Literature DB >> 883324

Urinary hydroxyproline in the management of breast cancer.

A Cuschieri.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 883324     DOI: 10.1007/bf01556842

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  18 in total

1.  The hypronosticon test in breast cancer.

Authors:  J G Roberts; M Williams; J M Henk; A S Bligh; M Baum
Journal:  Clin Oncol       Date:  1975-03

2.  Urinary hydroxyproline excretion and survival in cancer of the breast.

Authors:  A Cuschieri
Journal:  Clin Oncol       Date:  1975-06

3.  URINARY HYDROXYPROLINE EXCRETION IN METASTATIC CANCER OF BONE.

Authors:  W D PLATT; L H DOOLITTLE; J W HARTSHORN
Journal:  N Engl J Med       Date:  1964-08       Impact factor: 91.245

4.  Urinary hydroxyproline excretion in early and advanced breast cancer-a sequential study.

Authors:  A Cuschieri
Journal:  Br J Surg       Date:  1973-10       Impact factor: 6.939

5.  'Early' breast cancer, bone scanning, and the urinary excretion of hydroxyproline.

Authors:  D S Sumner; M Baum; V Parsons; M H Edwards
Journal:  Br J Surg       Date:  1973-04       Impact factor: 6.939

6.  Urinary hydroxyproline excretion in carcinoma of the breast.

Authors:  A Cuschieri; R A Felgate
Journal:  Br J Exp Pathol       Date:  1972-06

7.  Urinary peptide hydroxyproline before and during postpartum involution of human uterus.

Authors:  L R Klein; S S Yen
Journal:  Metabolism       Date:  1970-01       Impact factor: 8.694

8.  Urinary hydroxyproline excretion in patients with cancer.

Authors:  C E Guzzo; W N Pachas; R S Pinals; M J Krant
Journal:  Cancer       Date:  1969-08       Impact factor: 6.860

9.  Urinary hydroxyproline and calcium metabolism in patients with cancer.

Authors:  G Bonadonna; M J Merlino; W P Myers; M Sonenberg
Journal:  N Engl J Med       Date:  1966-08-11       Impact factor: 91.245

10.  Hydroxyproline excretion in malignant neoplastic disease.

Authors:  H F Hosley; E G Taft; K B Olson; S Gates; R T Beebe
Journal:  Arch Intern Med       Date:  1966-12
View more
  2 in total

1.  The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.

Authors:  A Nicolini; P Ferrari; A Sagripanti; A Carpi
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

2.  Pyridinium crosslinks as markers of bone resorption in patients with breast cancer.

Authors:  C R Paterson; S P Robins; J M Horobin; P E Preece; A Cuschieri
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.